[From General Practitioner magazine, June 1962]

when postoperative infection complicates convalescence...

CHLOROMYCETIN®

(chloramphenicol, Parke-Davis)

for broad antibacterial action

The incidence of postoperative wound infections, particularly among debilitated patients, presents a serious hospital problem.[1] These infections are caused in many cases by strains of staphylococci resistant to most antibiotics in common use.[1,2,3] In such instances, CHLOROMYCETIN should be considered, since "...the very great majority of the so-called resistant staphylococci are susceptible to its action."[4]

Staphylococcal resistance to CHLOROMYCETIN remains surprisingly infrequent, despite widespread use of the drug.[2,4,5-7] In one hospital, for example, even though consumption of CHLOROMYCETIN increased markedly since 1955, there was little change in the susceptibility of staphylococci to the drug.[7]

Characteristically wide in its antibacterial spectrum, CHLOROMYCETIN has also proved valuable in surgical infections caused by other pathogens—both gram-positive **and** gram-negative.[7,8]

CHLOROMYCETIN (chloramphenicol, Parke-Davis) is available in various forms, including Kapseals® of 250 mg., in bottles of 16 and 100.

See package insert for details of administration and dosage.

Warning: Serious and even fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) are known to occur after the administration of chloramphenicol. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Bearing in mind the possibility that such reactions may occur, chloramphenicol should be used only for serious infections caused by organisms which are susceptible to its antibacterial effects. Chloramphenicol should not be used when other less potentially dangerous agents will be effective, or in the treatment of trivial infections such as colds, influenza, or viral infections of the throat, or as a prophylactic agent.

Precautions: It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia or granulocytopenia, before they become irreversible, such studies cannot be relied upon to detect bone marrow depression prior to development of aplastic anemia.

References: (1) Minchew, B. H., & Cluff, L. E.: *J. Chron. Dis.* **13**:354, 1961. (2) Wallmark, G., & Finland, M.: *Am. J. M. Sc.* **242**:279, 1961. (3) Wallmark, G., & Finland, M.: *J.A.M.A.* **175**:886, 1961. (4) Welch, H., in Welch, H., & Finland, M.: Antibiotic Therapy for Staphylococcal Diseases, New York, Medical Encyclopedia, Inc., 1959, p. 14. (5) Hodgman, J. E.: *Pediat. Clin. North America* **8**:1027, 1961. (6) Bauer, A. W.; Perry, D. M., & Kirby, W. M. M.: *J.A.M.A.* **173**:475, 1960. (7) Petersdorf, R. G., *et al.*: *Arch. Int. Med.* **105**:398, 1960. (8) Goodier, T. E. W., & Parry, W. R.: *Lancet* **1**:356, 1959.

PARKE-DAVIS

PARKE, DAVIS & COMPANY, Detroit 32, Michigan



81-280 O - 68 - pt. 6 - 6